SIGA Technologies Reports Sharply Increased Loss, Negative Cash Flow Amidst EMA Mpox Setback; Declares Special Dividend

summarizeSummary

SIGA Technologies reported a significant increase in net loss and a shift to negative operating cash flow for Q1 2026, alongside an EMA recommendation against TPOXX use for mpox. The company also declared a substantial special cash dividend and secured a new MENA license agreement.

check_boxKey Events

• Financial Performance Deterioration

  Net loss increased significantly to $3.45 million in Q1 2026 from $0.41 million in Q1 2025, with total revenues decreasing to $6.24 million from $7.04 million in the prior year period.

• Shift to Negative Operating Cash Flow

  The company experienced a substantial shift to negative cash flow from operating activities, using $8.66 million in Q1 2026 compared to generating $7.06 million in Q1 2025.

• EMA Recommendation Against Mpox Use

  The European Medicines Agency (EMA) recommended that TPOXX no longer be used for mpox treatment, following clinical trial results, though efficacy for smallpox, cowpox, and vaccinia complications was confirmed.

• Special Cash Dividend Declared

  The Board of Directors declared a special cash dividend of $0.60 per share on March 26, 2026, totaling approximately $43.9 million, which was paid on April 23, 2026.

auto_awesomeAnalysis

SIGA Technologies' Q1 2026 results show a significant deterioration in financial performance, with an eight-fold increase in net loss and a substantial swing to negative operating cash flow. This, coupled with the EMA's recommendation against TPOXX use for mpox, presents considerable headwinds for the company's core business and future growth prospects in that indication. While the special cash dividend provides a notable return to shareholders and the new MENA license offers international expansion, these positive developments are balanced against the concerning financial trends and regulatory setback. Investors should monitor future revenue streams and cash burn closely, especially given the impact of the EMA decision on TPOXX's market potential.